Subscribe To

Price Alert Latest News Economic Calendar News

IMRX / Immuneering Corporation (IMRX) Q4 2022 Earnings Call Transcript

Immuneering Corporation (NASDAQ:IMRX ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Laurence Watts - Investor Relations, Gilmartin Group Benjamin Zeskind - President and Chief Executive Officer Brett Hall - Chief Scientific Officer Scott Barrett - Chief Medical Officer Mallory Morales - Vice President of Finance, Treasurer Conference Call Participants Swapnil Malekar - Piper Sandler Jeffrey Hung - Morgan Stanley Mark Breidenbach - Oppenheimer & Co. Inc. Michael Schmidt - Guggenheim Partners Operator Welcome to the Immuneering Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Read More

Demo Live Account See Partner Details

Content Topics

Immuneering

Corporation

IMRX

2022

Earnings

Call

Transcript

imrx

Stock

Posted: Mar 6 2023, 22:50

Author Name: Seeking Alpha

IMRX News

By GlobeNewsWire
October 4, 2023

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for

By Seeking Alpha
July 7, 2023

Immuneering Corp.: Early Stage Promise, But Long-Term Investment

IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going

By Zacks Investment Research
July 5, 2023

Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effective

By Zacks Investment Research
May 4, 2023

Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates

Immuneering Corporation (IMRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares

By Zacks Investment Research
April 11, 2023

Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?

Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate rev

By Zacks Investment Research
March 27, 2023

Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 102.5% in Immuneering Corporation (IMRX). While the effective

By The Motley Fool
March 24, 2023

Why Shares of Immuneering Jumped This Week

Immuneering is a clinical-stage biopharmaceutical that focuses on oncology therapies. The company's lead therapy is in a phase 1/2a trial.

By Zacks Investment Research
March 23, 2023

Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?

Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mig

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.